Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK

News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

06/13/2012 | 08:52am US/Eastern
   By Victoria Stilwell 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

React to this article
Latest news on MERCK & CO., INC.
10/05 MERCK : Results from Merck’s Phase 3 Study of Investigational Chronic Hepa..
10/05 MERCK : Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for..
10/05 Pacific trade deal adds to U.S. price quandary for biotech drugs
10/05 MERCK : Health and Human Services Department (HHS); Food and Drug Administration..
10/02 SITC : New Immunotherapy for Lung Cancer Offers Hope to Patients, SITC Reacts
10/02DJFDA Approves Merck's Keytruda for Most Common Form of Lung Cancer -- Update
10/02 MERCK : FDA expands Merck drug's approval to treat lung cancer
10/02 MERCK : FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients wit..
10/02DJFDA Approves Merck's Keytruda for Most Common Form of Lung Cancer
10/02DJFDA Approves Merck's Keytruda for Lung Cancer
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials